Sanuj Ravin­dran to lead Pelle­Pharm as CEO; Paul Hast­ings leaves On­coMed; Mod­er­na taps John Mendlein as pres­i­dent

→ A new pres­i­dent and CEO, Sanuj Ravin­dran, will lead Pelle­Pharm in­to this year’s Phase III tri­al for its skin can­cer drug. Pelle­Pharm, which spe­cial­izes in rare ge­net­ic der­ma­to­log­i­cal con­di­tions, has re­ceived break­through ther­a­py and or­phan drug des­ig­na­tions for patideg­ib, which treats Gor­lin syn­drome. Ravin­dran comes to Pelle­Pharm — and Bridge­Bio, Pelle­Pharm’s lead in­vestor, where he will be CEO-in-res­i­dence — from rare dis­ease biotech aTyr. For two years, he led cor­po­rate and fi­nan­cial strat­e­gy as chief busi­ness of­fi­cer. Once a prac­tic­ing physi­cian, Ravin­dran learned about the in­dus­try as a ven­ture cap­i­tal­ist for a decade be­fore div­ing in­to biotech at the Med­i­cines Com­pa­ny. He will be as­sist­ed at Pelle­Pharm by an ex­ec­u­tive team that just got big­ger: Al­ix Al­der­man has been named VP of reg­u­la­to­ry af­fairs and Gerd Kochen­do­er­fer is the new VP of tech­ni­cal op­er­a­tions and pro­gram man­age­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.